Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.112”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [112]
In the citing paper
“This issue can often be overcome using high-dose cyclophosphamide or the CXCR4 antagonist plerixafor125.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [125]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“dtd"[ ]> Introduction High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“11 Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma”
BackgroundRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citation
Cited by
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.(96) Patients who have received more than 4–6 cycles of lenalidomide may need plerixafor for stem cell mobilization.”
MethodSelf-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.(94) Patients who have received more than 4-6 cycles of lenalidomide may need plerixafor for stem cell mobilization.”
MethodSelf-citationDiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N. M., Stiff, P. J., Kaufman, J. L., Maziarz, R. T., Hosing, C., Früehauf, S., Horwitz, M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174946 · Cited by 789
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Self-citationGiralt, S., Costa, L., Schriber, J., DiPersio, J., Maziarz, R., McCarty, J., Shaughnessy, P., Snyder, E., Bensinger, W., Copelan, E., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2013.10.013 · Cited by 407
The role of Dickkopf-1 in bone development, homeostasis, and disease
Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., & Shaughnessy, J. D. (2009) · Blood · doi:10.1182/blood-2008-03-145169 · Cited by 408
“We confirmed that pretreatment with rDKK1 completely abolished Wnt3a-induced OPG mRNA and protein expression by mouse and human osteoblasts, and that coculture of osteoblasts with either a DKK1-expressing MM cell line or primary MM cells diminished OPG expression in the osteoblasts.68 Moreover, bone marrow sera from M…”
BackgroundInfluentialReeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 372
Self-citationPusic, I., Jiang, S. Y., Landua, S., Uy, G. L., Rettig, M. P., Cashen, A. F., Westervelt, P., Vij, R., Abboud, C. N., Stockerl-Goldstein, K. E., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.07.004 · Cited by 352
“Recent data suggests that this may not be the case in MM patients treated prior to stem cell harvest with lenalidomide containing therapy [38].”
BackgroundTreatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 331
“More recently, with increasing use of immunomodulatory drugs, lenalidomide in particular, studies have shown that extensive exposure to lenalidomide (beyond four to six cycles) may also compromise stem-cell yield.(140,141) Although some of the deleterious effects from alkylator and lenalidomide exposure can be overcom…”
BackgroundSelf-citationG-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent
Bendall, L. J., & Bradstock, K. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.011 · Cited by 304
“In autologous donors mobilization failure is more common and is strongly correlated with prior exposure to myelotoxic agents with DNA damaging agents such as melphalan and fludarabine and the thalidomide derivative lenalidomide [86–88].”
BackgroundGuidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
“Despite this, concerns have been raised about failure to harvest adequate stem cells after prolonged lenalidomide treatment and, as a result, it is now recommended that stem cells should be collected within 6 months of initiation of lenalidomide therapy (Kumar et al, 2007).”
BackgroundRajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Self-citationMultiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Self-citationCurrent status of autologous stem cell transplantation for multiple myeloma
Al Hamed, R., Bazarbachi, A. H., Malard, F., Harousseau, J.-L., & Mohty, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0205-9 · Cited by 236
Kumar, S., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N., Niesvizky, R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-205013 · Cited by 234
“Phase 3 trials of bortezomib in combination with dexamethasone with or without doxorubicin has shown excellent tolerability and improved response rates and progression-free survival compared with traditional VAD in the setting of initial therapy prior to SCT.17,20,47 Both lenalidomide and bortezomib have been combined…”
BackgroundInfluentialSelf-citationGiralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Kumar, S., Munshi, N. C., Dispenzieri, A., Kyle, R., et al. (2009) · Leukemia · doi:10.1038/leu.2009.127 · Cited by 231
Self-citationMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when Rd is used as induction therapy.(94) Thus, patients over the age of 65 and those who have received more than 4 cycles of Rd stem cells must be mobilized with either cyclophosphamide plus G-CSF or with plerixafor.”
MethodSelf-citationImproving stem cell mobilization strategies: future directions
Bensinger, W., DiPersio, J. F., & McCarty, J. M. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.410 · Cited by 218
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Self-citationMohty, M., Hübel, K., Kröger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.39 · Cited by 197
on behalf of the Italian Group for Stem Cell Transplantation (GITMO), Olivieri, A., Marchetti, M., Lemoli, R., Tarella, C., Iacone, A., Lanza, F., Rambaldi, A., & Bosi, A. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.82 · Cited by 181
Popat, U., Saliba, R., Thandi, R., Hosing, C., Qazilbash, M., Anderlini, P., Shpall, E., McMannis, J., Körbling, M., Alousi, A., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.02.011 · Cited by 169
“Further supporting our findings are other reports of lower stem cell yields and increased mobilization failure rates in patients who had received prior lenalidomide [27-29].”
BackgroundResultInfluentialAdvances in stem cell mobilization
Hopman, R. K., & DiPersio, J. F. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.01.001 · Cited by 161
“Prior chemotherapy Direct toxicity to HSCs and BM niche [12-19]”
BackgroundMyeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
Self-citationAdvances in stem cell mobilization
Motabi, I. H., & DiPersio, J. F. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.09.003 · Cited by 160
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Self-citationreview: Current status of stem cell mobilization
Gertz, M. A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08313.x · Cited by 153
“Recently, lenalidomide’s impact on reducing stem cell yield has been reported independently by multiple groups (Kumar et al, 2007; Paripati et al, 2008; Popat et al, 2009).”
BackgroundSelf-citationMultiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Self-citationMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Self-citationCosta, L. J., Alexander, E. T., Hogan, K. R., Schaub, C., Fouts, T. V., & Stuart, R. K. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.78 · Cited by 146
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Duarte, R. F., Shaw, B. E., Marín, P., Kottaridis, P. D., Ortiz, M., Morante, C., Delgado, J., Gayoso, J., Goterriz, R., Martínez‐Chamorro, C., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.54 · Cited by 130
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
Paripati, H. R., Stewart, A. K., Cabou, S., Dueck, A. C., Zepeda, V. J. J., Pirooz, N. A., Ehlenbeck, C., Reeder, C. B., Slack, J. L., Leis, J. F., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405100 · Cited by 136
Self-citationShah, N., Callander, N. S., Ganguly, S., Gul, Z., Hamadani, M., Costa, L. J., Sengsayadeth, S. M., Abidi, M. H., Hari, P., Mohty, M., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.03.002 · Cited by 140
“Finally, in carefully selected MM patients receiving lenalidomide-based inductions with intent for a delayed auto-HCT, the importance of early stem cell collection and cryopreservation cannot be overemphasized [15-17].”
BackgroundStiff, P. J., Micallef, I. N., Nademanee, A. P., Stadtmauer, E. A., Maziarz, R. T., Bolwell, B. J., Bridger, G. J., Marulkar, S., Hsu, F. J., & DiPersio, J. F. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.11.021 · Cited by 142
Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia · doi:10.1038/sj.leu.2405035 · Cited by 126
“1 for presenting additional data that confirm our initial observation of decreased stem mobilization following the use of lenalidomide-based therapies for newly diagnosed myeloma”
BackgroundKumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Buadi, F. K., Hayman, S. R., Dingli, D., Gay, F., Sinha, S., Leung, N., Hogan, W. J., et al. (2011) · Cancer · doi:10.1002/cncr.26422 · Cited by 127
“6) NS Median platelet count (range), million/mm(3) 140 (11-418) 154 (21-543) NS”
BackgroundSelf-citationGertz, M. A., Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Gastineau, D. A., Winters, J. L., & Litzow, M. R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.369 · Cited by 124
Self-citationGonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Khan, A. A. C., Dingli, D., Dispenzieri, A. A., Fonseca, R., Hayman, S. R., Kapoor, P., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0264-8 · Cited by 130
Self-citationMark, T., Stern, J., Furst, J. R., Jayabalan, D., Zafar, F., LaRow, A., Pearse, R. N., Harpel, J., Shore, T., Schuster, M. W., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.04.008 · Cited by 117
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Vallet, S., Palumbo, A. P., Raje, N. S., Boccadoro, M., & Anderson, K. C. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802005191 · Cited by 121
“This effect was time-dependent, suggesting that patients should collect CD34þ cells early if receiving lenalidomide or thalidomide treatment [75,76].”
BackgroundA Multi-Niche Microvascularized Human Bone-Marrow-on-a-Chip
Nelson, M. R., Ghoshal, D., Mejías, J. C., Rubio, D. A. F., Keith, E., & Roy, K. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2021.120683 · Cited by 109
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy
Shortt, J., Hsu, A. K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2012.599 · Cited by 113
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Ludwig, H., Beksaç, M., Bladé, J., Boccadoro, M., Cavenagh, J. D., Cavo, M., Dimopoulos, M. A., Drach, J. W., Einsele, H., Facon, T. T. F., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0203 · Cited by 108
D’Addio, A., Curti, A., Worel, N., Douglas, K., Motta, M. R., Rizzi, S., Dan, E., Taioli, S., Giudice, V., Agis, H., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.128 · Cited by 93
Peled, A., Abraham, M., Avivi, I., Rowe, J. M., Beider, K., Wald, H., Tiomkin, L., Ribakovsky, L., Riback, Y., Ramati, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1302 · Cited by 87
“However, even with the use of plerixafor, the mobilization of a sufficient number of SCs remains a difficult objective in a sizeable proportion of patients (41% NHL and 13% MM patients), particularly those treated with lenalidomide or fludarabine as induction therapy (8-10).”
BackgroundTreatment for High-Risk Smoldering Myeloma
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1310911 · Cited by 88
Crees, Z. D., Rettig, M. P., Jayasinghe, R. G., Stockerl-Goldstein, K. E., Larson, S. M., Árpád, I., Milone, G. A., Martino, M. V., Stiff, P. J., Sborov, D. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02273-z · Cited by 90
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
Miguel, J. F. S., Harousseau, J., Joshua, D., & Anderson, K. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2546 · Cited by 90
Sheppard, D., Bredeson, C., Allan, D., & Tay, J. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.01.008 · Cited by 85
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Current approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 82
Self-citationMultiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 85
Self-citationCosta, L. J., Miller, A. N., Alexander, E. T., Hogan, K. R., Shabbir, M., Schaub, C., & Stuart, R. K. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.170 · Cited by 72
Thalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 75
Chhabra, S., Callander, N. S., Watts, N., Costa, L. J., Thapa, B., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.029 · Cited by 74
Sinha, S., Gastineau, D. A., Micallef, I. N., Hogan, W. J., Ansell, S. M., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Gertz, M. A., Greiner, C. W., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.236 · Cited by 74
Self-citationCavallo, F., Bringhen, S., Milone, G., Ben‐Yehuda, D., Nagler, A., Calabrese, E., Cascavilla, N., Montefusco, V., Lupo, B., Liberati, A. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.131 · Cited by 67
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 70
“Reduced stem cell yields after prolonged induction treatment with lenalidomide are well described.(113) Cyclo-G mobilization has been reported to give better yields post-lenalidomide induction.”
BackgroundMicallef, I. N. M., Ho, A. D., Klein, L. M., Marulkar, S., Gandhi, P. J., & McSweeney, P. A. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.118 · Cited by 61
“11 Although lenalidomide is a promising treatment for newly diagnosed patients, it can impair subsequent stem cell mobilization and collection both in frontline and salvage settings”
Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J., Laumann, K., Greipp, P. R., Lust, J. A., Gertz, M. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22053 · Cited by 61
Self-citationTuchman, S. A., Bacon, W., Huang, L., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Chute, J. P., Sullivan, K. M., Engemann, A. M., Yopp, A., et al. (2014) · Journal of Clinical Apheresis · doi:10.1002/jca.21360 · Cited by 65
“Newer MM therapies such as lenalidomide impair stem cell collection [14] and the finding that patients treated with lenalidomide can often be mobilized with the addition of Cy [15,16] amplified the necessity for Cy in recent years.”
Multiple Myeloma in the Time of COVID-19
Saleh, A. S. A., Sher, T., & Gertz, M. A. (2020) · Acta Haematologica · doi:10.1159/000507690 · Cited by 57
“There are no major concerns for collection, as patients receiving IMiD-based therapy can successfully undergo stem cell collection after 6 cycles [34] using granulocyte colony-stimulating factor (G-CSF).”
MethodSelf-citationVishnu, P., Roy, V., Paulsen, A., & Zubair, A. C. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03206.x · Cited by 62
“93 Time to PLT engraftment 13 (10-23) 13 (10-47) 0.”
Self-citationPantin, J. M., Purev, E., Tian, X., Cook, L., Donohue-Jerussi, T., Cho, E., Reger, R. N., Hsieh, M. M., Khuu, H. M., Calandra, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.147132 · Cited by 57
Afifi, S., Adel, N., Devlin, S. M., Duck, E., Vanak, J. M., Landau, H. J., Chung, D. J., Lendvai, N. K., Lesokhin, A. M., Korde, N., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.322 · Cited by 60
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
Bensinger, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6863 · Cited by 61
Bazarbachi, A. H., Hamed, R. A., Malard, F., Bazarbachi, A. A., Harousseau, J., & Mohty, M. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00645-1 · Cited by 61
Costa, L. J., Abbas, J. A., Hogan, K. R., Kramer, C., McDonald, K., Butcher, C., Littleton, A., Shoptaw, K. B., Kang, Y., & Stuart, R. K. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.60 · Cited by 55
Advances in mobilization for the optimization of autologous stem cell transplantation
Vose, J. M., Ho, A. D., Coiffier, B., Corradini, P., Khouri, I. F., Sureda, A. M., van Besien, K., & DiPersio, J. F. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903096701 · Cited by 54
Silvennoinen, R. H., Anttila, P. M., Säily, M., Lundán, T., Heiskanen, J., Siitonen, T., Kakko, S., Putkonen, M., Ollikainen, H., Terävä, V., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.236 · Cited by 59
Micallef, I. N., Stiff, P. J., Nademanee, A. P., Maziarz, R. T., Horwitz, M. E., Stadtmauer, E. A., Kaufman, J. L., McCarty, J. M., Vargo, R. L., Cheverton, P., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.039 · Cited by 57
“These include patients with NHL, elderly patients [19], heavily pretreated patients [20-22], and patients with MM who have previously received multiple cycles of lenalidomide or undergone auto-HSCT [23].”
BackgroundPozotrigo, M., Adel, N., Landau, H. J., Lesokhin, A. M., Lendvai, N. K., Chung, D. J., Chimento, D., Riedel, E., Chen, X., REICH, L. M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.281 · Cited by 50
Wood, W. A., Whitley, J., Moore, D. T., Sharf, A., Irons, R. N., Rao, K. V., Serody, J. S., Coghill, J. G. J., Gabriel, D., & Shea, T. C. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.06.021 · Cited by 52
Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Hayman, S. R., Buadi, F. K., & Hogan, W. J. (2010) · Blood · doi:10.1182/blood-2009-07-235531 · Cited by 48
Self-citationAutologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies
Parrondo, R. D., Ailawadhi, S., Sher, T., Chanan-Khan, A. A., & Roy, V. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00335 · Cited by 50
Self-citationImmunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 49
Self-citationMobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies
Jantunen, E., & Kvalheim, G. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01520.x · Cited by 52
“Lenalidomide is marrow toxic, and longer therapy with this drug has resulted in failure to mobilize with G-CSF alone in a significant number of patients with myeloma (35, 36).”
BackgroundMalard, F., Kröger, N. M., Gabriel, I. H., Hübel, K., Apperley, J. F., Basak, G. W., Douglas, K., Geraldes, C., Jakšić, O., Kořístek, Z., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.003 · Cited by 47
“60 years), progressive disease, bone marrow involvement, or previous chemotherapy including drugs such as fludarabine [7] or lenalidomide [8].”
BackgroundMoreb, J. S., Byrne, M. T., Shugarman, I. L., Zou, F., Xiong, S., May, W. S., Norkin, M., Hiemenz, J., Brown, R., Cogle, C. R., et al. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21556 · Cited by 46
Treatment of plasma cell dyscrasias with lenalidomide
Dimopoulos, M. A., Kastritis, E., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.123 · Cited by 45
Self-citationSolomon, S. R., Matthews, R. H., Barreras, A. M., Bashey, A., Manion, K., McNatt, K., Speckhart, D. S., Connaghan, D. G., Morris, L. E., & Holland, H. K. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.234 · Cited by 41
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 43
Palumbo, A. P., Dimopoulos, M. A., Miguel, J. F. S., Harousseau, J., Attal, M., Hussein, M. A., Knop, S. T., Ludwig, H., von Lilienfeld‐Toal, M., & Sonneveld, P. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.07.003 · Cited by 41
Costa, L. J., Nista, E., Buadi, F. K., Lacy, M. Q., Dispenzieri, A. A., Kramer, C., Edwards, K. H., Kang, Y., Gertz, M. A., Stuart, R. K., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.003 · Cited by 42
Self-citationUy, G. L., Costa, L. J., Hari, P., Zhang, M.-J., Huang, J.-X., Anderson, K. C., Bredeson, C., Callander, N. S., Cornell, R. F., Perez, M. A. D., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.190 · Cited by 43
Self-citationFrüehauf, S., & Tricot, G. J. K. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.002 · Cited by 43
“Numerous factors, including age, previous rounds of chemotherapy, previous radiation therapy, exposure to lenalidomide or alkylating agents, and bone marrow involvement, have been identified as risk factors for poor mobilization in patients with lymphoma and MM [15,47-60].”
BackgroundNovel agents and approaches for stem cell mobilization in normal donors and patients
Bakanay, Ş. M., & Demirer, T. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.170 · Cited by 41
Sánchez‐Ortega, I., Querol, S., Encuentra, M., Ortega, S., Serra, A., Sánchez-Villegas, J., Grífols, J.-R., Pujol-Balaguer, M. M., Pujol-Bosch, M., Martí, J. M., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.196 · Cited by 39
Lenalidomide: A new therapy for multiple myeloma
Palumbo, A. P., Miguel, J. F. S., Sonneveld, P., Moreau, P., Drach, J. W., Morgan, G. J., & Einsele, H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.005 · Cited by 37
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Rajkumar, S. V. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.354.3798330 · Cited by 38
Self-citationMultiple myeloma: chemotherapy or transplantation in the era of new drugs
Palumbo, A., & Rajkumar, S. V. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01431.x · Cited by 39
“In patients who are transplantation candidates but who want to reserve ASCT as a delayed option for relapsed ⁄ refractory disease, stem cells should be collected early in the disease course and cryopreserved (42).”
BackgroundSelf-citationCrees, Z. D., Rettig, M. P., & DiPersio, J. F. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231174304 · Cited by 36
Novel agents and new therapeutic approaches for treatment of multiple myeloma
Ria, R., Reale, A., & Vacca, A. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i2.73 · Cited by 40
Large volume leukapheresis: Efficacy and safety of processing patient’s total blood volume six times
Bojanić, I., Dubravčić, K., Batinić, D., Ćepulić, B. G., Mazic, S., Hren, D., Nemet, D., & Labar, B. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.01.005 · Cited by 35
“That is sometimes challenging in heavily pretreated patients, particularly those who previously received lenalidomide [4,35].”
Background
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., & Gertz, M. A.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Kumar, S
- ORCID
- Venue
- Leukemia
- Published
- 2007-06-21
- Volume
- 21
- Issue
- 9
- Pages
- 2035-2042
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2036985459
- Semantic Scholar
- 831eb40600d3fcbfc29f2b9cc655e7c78f420e1f
- Cited by
- 351
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 29 · 2012: 27
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- lenalidomide, peripheral blood stem cell mobilization, stem cell engraftment, multiple myeloma, newly diagnosed multiple myeloma, granulocyte colony-stimulating factor, CD34+ cell yield, apheresis, VAD chemotherapy, bortezomib, mobilization failure
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Vincristine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hormonal, Hematopoietic Stem Cell Mobilization, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.